Company profile
Genomic Technology for Cell & Gene Therapies
Our platform accelerates the characterisation of novel gene editing technologies to unlock the next wave of cell & gene therapies.
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
CS01 | Transaction MzUxNTM2OTkyNGFkaXF6a2N4
Published 12 Apr 2026 05:55
Last confirmation statement made up date
Last accounts made up date
SH01 | Transaction MzQ0MTg2MzkzM2FkaXF6a2N4
Published 04 Nov 2024 09:53
AA | Transaction MzQzNjM3NDUxNWFkaXF6a2N4
Published 18 Sep 2024 11:12
AP01 | Transaction MzQzNDYxMzEyOWFkaXF6a2N4
Published 05 Sep 2024 09:00
AP01 | Transaction MzQzNDYxMTI5NWFkaXF6a2N4
Published 05 Sep 2024 08:45
TM01 | Transaction MzQzNDYxMTE0N2FkaXF6a2N4
Published 05 Sep 2024 08:44
Company registered at Companies House
Broken String Biosciences develops genome analysis technology.
Broken String Biosciences was formed to take advantage of the novel method INDUCE-seq that was developed during this award. The company aims to provide quantitative and accurate genome-wide DSB measurement to both industry and academic customers for a range of of biomedical applications.
VC seed funding secured in October 2021
No notable impacts at this time.
1 Jul 2025 to 30 Jun 2027
no public description
